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ONCOLOGY REPORTS
Abstract. Survival rates in oncological patients have been 
steadily increasing in recent years due to the greater effec‑
tiveness of novel oncological treatments, such as radio‑ and 
chemotherapy. However, these treatments impair the reproduc‑
tive ability of patients, and may cause premature ovarian failure 
in females and azoospermia in males. Fertility preservation 
in both female and male oncological patients is nowadays 
possible and should be integrated as part of the oncological 
healthcare. The main objective of this review was to describe 
the different existing options of fertility preservation in 
patients undergoing gonadotoxic cancer treatments, as well as 
the differences in success rates that may appear in the different 
techniques evaluated. Emerging techniques are promising, 
such as the cryopreservation in orthotopic models of ovarian 
or testicle tissues, artificial ovaries, or in vitro culture prior 
to the autotransplantation of cryopreserved tissues. However, 
oocyte vitrification for female patients and sperm banking for 
male patients are considered the first line fertility preserva‑
tion option at the present time for cancer patients undergoing 
treatment. Certainly, new fertility preservation techniques will 
continue to develop in the following years. However, despite 
the growing advances in the subject, optimal counselling from 
healthcare professionals should always be present.
Contents
1. Introduction
2. Fertility preservation techniques in females and males
3. Fertility preservation techniques in females
4. Emerging techniques
5. Fertility preservation techniques in males
6. Conclusions and future perspectives
1. Introduction
More than 70,000 adolescent and young adult (AYA) patients, 
with ages between 15 and 39 years, are diagnosed with cancer 
every year only in the United States. The incidence of cancer 
in children younger than 15 years of age is also approximately 
10,000 cases per year (1).
In Europe, >15,000 AYAs are diagnosed with cancer each 
year, according to the International Society of Paediatric 
Oncology (https://siop‑online.org/). In 2004, the Spanish 
Registry of Childhood Tumors (RETI‑SEHOP) concluded 
that approximately 1,100 children in Spain are diagnosed 
with cancer annually (https://www.uv.es/rnti/index.html). 
The incidence of cancer in children in Spain is similar to that 
in other European countries, with approximately 160 new 
cases per million children each year, aged between zero and 
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14 years, according to the Spanish Federation of Parents 
of Children with Cancer (FEPNC; http://cancerinfantil.
org/cancer‑infantil‑cifras/). The survival rates of these 
patients have been steadily increasing in recent years due 
to the greater efficacy of novel oncological treatments. In 
fact, the 5‑year survival rate for pediatric cancer patients 
approaches 80% (2). However, treatments entailing 
chemotherapy or radiotherapy, often result in impaired or 
absent reproductive ability. Moreover, only approximately 
half of patients report any reproductive issues, having 
previously been informed about the therapeutic options 
of fertility preservation (FP), which has been identified as 
the second most important aspect among young patients, 
following survival. In order to improve the quality of life and 
the survival of patients, the improvement of FP techniques 
has become an important topic in the field of research 
over the past years (3). In fact, the concept of oncofertility 
has recently appeared in the form of an interdisciplinary 
integrated network, based on medical methods, which is 
designed to maximize the reproductive future of oncological 
patients by offering various FP techniques. Furthermore, a 
standardization of the FP healthcare for oncological patients 
is required. Currently, two major international networks have 
been created for this purpose: The International Network on 
Cancer, Infertility and Pregnancy (INCIP) and the European 
Society of Gynecological Oncology (ESGO) (2).
2. Fertility preservation techniques in females and males
A literature review was conducted by searching for publica‑
tions in PubMed between September, 2017 and May, 2018 with 
the following keywords and their combinations: ‘fertility’, 
‘preservation’, ‘women’, ‘male’, ‘prepuberal’, ‘young adults’, 
‘gonadotoxic treatment’, ‘cancer treatment’ and ‘oncofertility’.
At the 20th week of embryogenesis, women reach the 
maximal number of germ cells in the genital rides, with 
approximately 6‑7 million potential oocytes, known as the 
primordial follicles. However, only 1 million of these will 
remain at birth and only approximately 400,000 oocytes 
will survive to puberty. This number, known as the ovarian 
reserve, will decrease, reaching 1,000 oocytes at the time of 
menopause, due to the approximately 450 monthly ovulatory 
cycles, during which process most oocytes undergo atresia 
(degeneration and reabsorption) (4). The preservation of the 
ovarian reserve is necessary to maintain overall women's 
health, as it plays a role not only in oocyte development and 
fertility, but also in other systems, such as the cardiovascular 
system and osseous system (5).
The degree of the depletion of the ovarian reserve differs 
between chemotherapy and radiotherapy. As regards chemo‑
therapy, it varies depending on the age of the patient (the 
younger the patient, the lesser the risk of ovarian failure), the 
chemotherapy agent used (alkylating agents being of greatest 
risk) and the duration of the treatment. Oocytes are very sensi‑
tive to radiation. Exposure to 20‑30 Gy of radiation or total 
body radiation of 15 Gy lead to the loss of ovarian function 
[premature ovarian failure (POF)] (3).
The following techniques are available to women who are 
willing to preserve their fertility prior to, or during chemo‑ 
and radiotherapy: Embryo cryopreservation, immature or 
mature oocyte cryopreservation, ovarian tissue cryopreser‑
vation (OTC) and ovarian transposition. In this review, we 
specifically focus on the oocyte and OTC. Other experimental 
techniques, such as the activation of ovarian follicles, in vitro 
follicle culture, artificial ovaries and novel fertoprotective 
agents, may appear to be promising, although further research 
is still required (6).
In males, the onset of production of spermatozoa begins at 
puberty and it is known as spermarche. Unlike women, from 
the moment of the spermarche, spermatogenesis is maintained 
during the entire duration of a man's life, on account of the 
spermatogonia type A, among others (7). Testicular stem 
cells differentiate into spermatogonia, which will eventually 
become spermatozoa under the process of spermatogenesis. 
Spermatogonia in the testes are extremely sensitive to radia‑
tion, regardless of age. Leydig cells, on the other hand, are 
more sensitive to radiation prior to the onset of puberty, 
whereas in adulthood, they become more resistant to radia‑
tion (8). Consequently, adult patients may preserve Leydig cell 
function and testosterone production following radiotherapy 
despite being azoospermic. Furthermore, if a population of 
spermatogonial stem cells (SSCs) remains after cancer treat‑
ment, as the effect is dose‑dependent, the regeneration of 
spermatozoa may continue for years (9). Those at the highest 
risk of developing permanent sterility are children and adoles‑
cents with testicular cancer, leukemia and Ewing's sarcoma. 
Sperm banking is the recommended FP technique for males, 
although the cryopreservation of SSCs is also available.
3. Fertility preservation techniques in females
Embryo cryopreservation. This technique has established 
success rates and is a widely used and reliable method. It is 
like an in vitro fertilization (IVF) protocol, which has been 
performed for over 30 years. Women undergo controlled 
ovarian stimulation (COS) with gonadotropin injections to 
promote multifollicular growth. After 10‑14 days, oocyte 
retrieval is performed, normally under conscious sedation and 
with transvaginal ultrasound‑guided needle aspiration (10). 
The oocytes are then fertilized in the laboratory and are 
cryopreserved for future use, commonly in their blastocyst 
phase (4).
The disadvantages of this technique are mainly three 
as follows: The need of a stable male partner, ethical 
issues regarding embryo disposition and the time required 
for ovarian stimulation. COS normally begins during 
the early follicular phase. When a patient is diagnosed 
in her early follicular phase, ovarian stimulation with 
gonadotropin‑releasing hormone (GnRH) antagonist begins 
immediately. However, if the patient is in any other phase, 
the IVF standard protocols require the patient to wait up 
to 3 weeks before the process begins (10). Therefore, this 
method is not a viable option for women whose aggressive 
cancer treatment is of highest priority, as the IVF standard 
protocols require a wait of up to 3 weeks before the process 
begins (10). It is also not recommended in women with 
hormone‑sensitive cancers and is not possible for prepu‑
bertal girls. It is also not recommended in women with 
hormone‑sensitive cancers and not possible for prepubertal 
girls.
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There are three main cryopreservation techniques: 
Slow‑freezing, ultra‑rapid and vitrification. Slow‑freezing 
involves a step‑wise programmed decrease in temperature (11), 
achieving a freezing equilibrium due to the exchange of the 
extra‑ and intracellular fluids without causing meaningful 
osmotic and deformation cellular effects. However, ice crystals 
can be formed within the cells, which can result in extremely 
harmful effects (12). The procedure is long‑lasting (approxi‑
mately 1 or 2 h) and requires expensive instrumentation and 
large quantities of liquid nitrogen, among others. Vitrification 
converts water into solid glass‑like cells, avoiding ice crystal 
formation, both intracellular and extracellular (13). Expensive 
instrumentation it is not required, and only several minutes 
are needed. Furthermore, a meta‑analysis in 2013 revealed 
that the rates of oocyte survival, fertilization and implanta‑
tion where higher in vitrification than in slow‑freezing 
methods (14). For these reasons, vitrification is nowadays the 
preferred technique.
Data on pregnancy and live both rates in cancer patients 
after frozen embryo transfer are limited. Live birth rates 
in non‑oncological patients <35 years of age amount to 
38.7% per frozen embryo transfer and to 34,8% for oocyte 
donor cycles (15).
Oocyte cryopreservation. As an alternative to embryo 
cryopreservation, this technique is the preferred option 
for postpuberal and adolescent females, women without 
a stable partner, and for those who do not wish to use 
a sperm donor. It overcomes the ethical and religious 
issues that emerge from the embryo preservation. Clinical 
outcomes in the oocyte vitrification strategy are superior to 
slow‑freezing and thawing (16). With oocyte vitrification, 
women are able to conceive in the future and maintain their 
reproductive autonomy. However, it is not appropriate for 
patients who are in urgent need of treatment or patients with 
hormone‑sensitive cancers, as the procedure also includes 
COS. The oocytes can be cryopreserved as mature eggs 
or as immature germinal vesicle oocytes. Mature oocyte 
cryopreservation is performed with the oocytes whose 
development is terminated in metaphase II. Nowadays, this is 
the preferred method for postpuberal patients and for patients 
whose chemotherapy and radiotherapy can be delayed. 
Immature oocytes obtained by aspiration and followed by 
in vitro maturation (IVM) techniques is a suitable option for 
prepubertal girls and women with hormone‑sensitive cancers 
or with polycystic ovarian syndrome (PCOS), since COS is 
not required. This also allows the possibility of immediate 
cancer treatment. Oocytes will be matured in vitro (through 
IVM) as the cryopreservation of mature oocytes has yielded 
better survival outcomes than immature cryopreserved 
oocytes (17). The retrieval of immature oocytes can also be 
achieved during an OTC procedure.
OTC. Although this technique is still considered experi‑
mental, it is currently the only option for pediatric patients 
and for patients with hormone‑dependent diseases, as it is 
COS‑independent and does not delay the oncological treat‑
ment. It does not require a male partner or a sperm donor.
OTC is an invasive procedure, as it requires general anes‑
thesia to surgically remove the ovarian tissue. This tissue, 
with a high content on follicles, is cryopreserved and can then 
be used as for the following procedures: i) Orthotopic implan‑
tation (reimplantation into the pelvic cavity; e.g., remaining 
ovarian tissue or peritoneum) or heterotopic implantation 
outside of the ovaries (e.g., rectum, pectoralis muscle, abdom‑
inal wall and chest wall); ii) isolation of follicles from the 
thawed tissue for in vitro growth, maturation and fertilization. 
During OTC, it is possible to aspirate immature oocytes from 
antral follicles of the ovarian tissue. Isolated oocytes can be 
cryopreserved or matured in vitro (through IVM) for later 
vitrification (18).
Either ovar ian cor tical t issue cryopreservation 
(slow‑freezing) or whole ovary cryopreservation can be 
performed. All egg‑containing follicles are in the outer 
one‑millimeter layer of the ovary, and thus the removal of this 
layer of tissue is sufficient for cryopreservation. The success 
rate of live‑birth after reimplantation is approximately 30% (6). 
The cryopreservation of the whole ovary remains a technical 
challenge due to the bigger size of the tissue, which hinders a 
homogeneous and adequate dispersion of cryoprotectant, and 
the vascular damage in form of ice crystals. Further studies 
are required in order for this technique to be used in standard 
clinical practice.
Up to 2015, 60 live birth cases had been reported with OTC 
in adult patients. However, the total number of re‑implantation 
performed in each center until that time was unknown; thus, 
no success rates could be concluded (19). Prior to menarche, 
only one live birth following the autografting of cryopre‑
served tissue has been published (20), at least to the best of 
our knowledge. In 2015, Donnez et al (19) published a large 
case series (n=111) which revealed a pregnancy rate proportion 
of 29% (n=32). Two women delivered 3 babies each, proving 
the efficacy of the technique and the possibility of conceiving 
naturally after only one procedure.
The most worrisome concern of OTC is the possibility of 
the re‑introduction of carcinogenic cells into the cured patient 
or the subsequent malignant transformation of the ovarian 
tissue, which has been already reported (21). For this reason, 
a thorough examination of the ovarian tissue prior to cryo‑
preservation and reimplantation is required.
Ovarian transposition (oophoropexy). This procedure aims to 
prevent ovarian damage during radiation therapy by relocating 
the ovaries away from the radiation field. Therefore, it will be 
of use in women who will undergo pelvic or low abdominal 
radiation therapy without additional gonadotoxic chemo‑
therapy (22). According to the radiation field outlined by 
the radiation oncologist, the surgeon will decide the optimal 
location in the abdominal wall for ovarian transposition. 
Altogether, the ovaries will not be harmed by the therapy and 
ovarian failure will be prevented. The procedure is normally 
performed laparoscopically before the commencement of 
radiation. Success rates are not conclusive, as they vary from 
16 to 90% (23).
Fertoprotective adjuvant agents. Another approach 
to preserving fertility is to protect the follicles during 
oncological treatment by administrating fertoprotective 
agents. One example is the use of GnRHa agonists, which 
are administrated 10 days prior to the commencement 
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of thechemotherapy. GnRH analogues interfere with 
the hypothalamic‑pituitary‑gonadal axis and inhibit the 
ovarian function by suppressing gonadotrophin levels to 
prepubertal levels (3). Two meta‑analysis of randomized 
trials concluded a reduced risk of POF in young breast cancer 
patients (24,25), whereas its use was unclear in ovarian 
cancer and lymphoma (25). Another study demonstrated 
no effect in young patients with lymphoma (26). The 
quality of the evidence is insufficient to draw meaningful 
conclusions; high‑quality studies are required to examine the 
long‑term effects of the use of GnRHa on premature ovarian 
insufficiency (POI).
4. Emerging techniques
Activation of ovarian follicles. Cryopreserved ovarian tissue 
from prepubertal patients and patients with POF contains 
immature primordial follicles, which need to be activated in 
order to begin developing. This can be induced either in vivo 
[by interrupting the Hippo signaling pathway (27)] or in vitro, 
prior to autotransplantation, by activating the phosphati‑
dylinositol 3‑kinase (PI3K)/phosphatase and tensin homolog 
(PTEN)/protein kinase B (AKT)/Forkhead box O3 (FOXO3) 
pathway, which regulates primordial follicle activation in 
oocytes (27). This pathway also plays a crucial role in the 
follicle‑stimulating hormone (FSH) stimulation of granulosa 
cell differentiation in antral follicles and in oocyte matura‑
tion of preovulatory follicles (27). This may be a promising 
fertility option for prepubertal patients and patients with 
primary ovarian insufficiency, whose cryopreserved tissue 
contains immature primordial follicles suitable for this tech‑
nique. In vitro protocols involving the PTEN/AKT pathway 
are being developed in order to increase the pool of viable 
activated follicles available for in vitro growth (IVG) proce‑
dures (28).
In vitro follicle culture. This technique may be an option 
for patients who require urgent oncological treatment, and 
therefore are not good candidates for oocyte or embryo cryo‑
preservation, such as patients with acute leukemia or acute 
myeloblastic leukemia (AML). OTC is the available option 
momentarily for these patients. However, the possibility of 
re‑seeding original cancer cells from the ovarian tissue exists, 
and therefore other alternatives need to be raised.
The ovarian follicle culture in vitro, aims to mitigate the 
risk of re‑implanting malignant cells from the cryopreserved 
ovarian tissue. It is therefore useful in patients with cancers 
whose metastasis appear often in the ovary or patients with 
BRAC1 and BRAC2 mutations, due to the increased risk of 
an ovarian cancer, which would not make possible the trans‑
plantation of cryopreserved ovarian cortex (29). However, 
the complete maturation of primordial follicles has not been 
achieved in humans yet (30).
In this procedure, individual follicles are isolated from 
the patient's bank tissue, which will afterwards be matured 
in vitro to become a functioning oocyte. These will be 
fertilized, and the embryos will be transferred to the uterus. 
The follicles can be cultured in two‑dimensional (2D) or 
three‑dimensional (3D) systems. These 3D culture methods 
are the most successful in maintaining the sphericity and 
the communications between cells (29) and have also shown 
greater follicular viability, follicle and oocyte diameters and 
hormone production (3).
Artificial ovaries. The creation of an artificial ovary for trans‑
plantation is a very promising fertility‑restoring technique. 
Isolated preantral follicles obtained from ovarian cryopre‑
served tissue, together with other ovarian cells in a 3D‑matrix, 
or scaffold, result in a ovary‑like environment, which could 
allow the growth of follicles and therefore could restore both 
fertility and endocrine function of the ovary once they are 
transplanted (3). Luyckx et al (31) achieved the survival and 
growth of murine ovarian follicles (primary, secondary and 
antral follicles) within 1 week following the transplantation of 
ovarian cells in a fibrin matrix. Moreover, Laronda et al (32) 
accomplished the initiation of puberty in ovariectomized mice 
following an artificial ovary transplant.
Specific target tissue drugs. Both nanoparticles and fertopo‑
tective agents share the aim of protecting ovarian cells during 
gonadotoxic oncological treatments. These are discussed 
below:
i) Nanoparticles. This procedure entails the encapsulation of 
the therapeutic agent in order to reduce its plasma clearance 
and therefore its toxicity. For such a purpose, a nanopar‑
ticulate formulation of the therapeutic agent is developed 
and encapsulated within liposomal vesicles or ‘nanobins’ 
(NB) (33). Ahn et al (34) demonstrated a superior antitumor 
efficacy of the nanoparticulate formulation of arsenic 
trioxide (As2O3) in nanobins [NB(Ni,As)] in a murine model 
of lymphoma as well as a reduced fertotoxicity.
ii) Novel fertoprotective agents. Current research focus on 
two different pathways: a) Anti‑apoptotic agents, such as 
imatinib, sphingosine‑1‑phosphatase (AS101), granulocyte 
colony‑stimulating factor (G‑CSF), thyroid hormone (T3) 
and tamoxifen (28), and they have shown to diminish follicle 
loss in animal models (35); and on b) agents which prevent 
follicle activation, such as AS101, an immunomodulator 
interacting with the PI3K/PTEN/AKT follicle activa‑
tion pathway (36) and the anti‑Mullerian hormone (35). 
In summary, a number of novel fertoprotectives agents to 
protect oocytes against gonadotoxic treatments are being 
investigated and may be available soon (3).
5. Fertility preservation techniques in males
In males undergoing gonadotoxic treatment, both sperm 
cryopreservation or testicular tissue cryopreservation are 
currently available (3,6). The American Society of Clinical 
Oncology (ASCO) guidelines recommend that oncologists 
inform about the risk of infertility in patients with cancer 
during their reproductive stages of life, as well as to refer 
them to specialists in fertility treatment.
Cryopreservation of spermatozoa. The cryopreservation 
of ejaculated semen is the recommended FP technique for 
adult males and pubertal boys producing sperm in the ejacu‑
late, who will be undergoing gonadotoxic treatment (37). For 
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patients receiving radiation therapy only, gonadal shielding 
may be an option if sperm collection is not possible.
The spermarche begins at puberty, but it is not exactly 
known when this onset begins, since clinical parameters, such 
as Tanner stage or increase on reproductive hormones, do not 
always correlate with spermermatogenesis onset, according 
to some data from urine examination and electro‑ejaculation 
in pubertal boys (38,39). The successful sperm collection 
following masturbation has been reported for boys aged 
12 years and older (40,41).
The procedure includes the collection of, ideally, at least 
3 semen samples, with an abstinence period of at least 48 h in 
between samples, and the following cryopreservation of the 
sperm samples, although often more than one semen sample 
must be taken in the same day to avoid the oncological treat‑
ment delay (7). In the case of ejaculation failure or when no 
spermatozoa are found in the ejaculate, sperm can be retrieved 
by epidydimal sperm aspiration, either percutaneous (PESA) 
or with microsurgery (MESA), testicular sperm extraction 
(TESE) or electro‑ejaculation (42,43).
Assisted reproductive treatment such as IVF and intra‑
cytoplasmic sperm injection (ICSI) are afterwards required. 
ICSI has the advantage of also allowing reproduction when 
the semen is of very poor quality or with only a few sperma‑
tozoa (7).
The pregnancy rates vary from 12% for intrauterine 
insemination to 32% for ICSI. To date, no follow‑up data 
for large cohorts of children born after assisted reproductive 
treatment using frozen‑thawed sperm of men with cancer 
are available in the literature, at least to the best of our 
knowledge.
It is worth mentioning that the European Germ Cancer 
Consensus Group and ASCO strongly recommend informing 
patients about the possibility of cryopreservation tech‑
niques before undergoing orchiectomy or gonadotoxical 
treatment (30). Unfortunately, such recommendations are 
oftentimes not followed by health‑care professionals, and 
many patients remain without counseling in the matter.
Cryopreservation of SSCs in prepubertal children. Prepubertal 
children do not undergo spermatogenesis yet, and therefore 
they do not have mature sperm in their testes. Hence, the 
cryopreservation of spermatozoa is not possible. The only 
possibility for them is to preserve testicular tissue, which 
contains SSCs.
In an analogous manner to the cryopreservation of ovarian 
tissue in women, the testicular tissue can be obtained (through 
a testicular biopsy) and cryopreserved in form of spermato‑
gonia or in form of testicular tissue (using slow‑freeze or 
ultra‑rapid techniques). This will be thereafter available to 
use when the patient is free of oncological illness and desires 
to have children. Once the tissue is thawed, it would allow 
in vitro spermatogenesis (44) or autotrasplantation of the 
cryopreserved tissue, either by infusion of a cell suspension 
into the seminiferous tubules or intratesticular grafting of the 
tissue (7).
The reintroduction of testicular stem cells into the 
seminiferous tissue could restart the sperm production (7). 
Orthotopic transplantation entails the risk of re‑seeding 
malignant cancer cells (e.g., in patients with leukemia), as 
occurs with ovarian autotransplantation. To mitigate the 
problem, a decontaminated cell suspension could be a possible 
solution (45). In vitro culture of testicular cells to obtain mature 
spermatozoa also circumvents the risk of reseeding malignant 
cells in the auto‑transplant of testicular tissue, being another 
branch of research at the moment (46). It is important to stress 
that fertility restoration strategies by auto‑transplantation of 
cryopreserved testicular tissue have not been tested yet for 
safe clinical use in humans and therefore it is still considered 
experimental (6). More research is still needed regarding the 
use of frozen‑thawed tissue to obtain mature spermatozoa 
in vitro (9).
6. Conclusions and future perspectives
Oncological healthcare is nowadays far from being solely the 
cure of cancer. Providing hope of future fertility following 
oncological treatment, significantly increases the quality of 
life of the patients and helps them to cope emotionally with 
cancer (30). FP in both female and male oncological patients 
is nowadays possible and should be integrated as part of 
the oncological health care. Different techniques exist and 
the most appropriate should be chosen depending on the 
characteristics of the patients: Male, female, prepubertal or 
postpubertal. Some of these have already proven successful 
outcomes whereas others, newer and more innovative, are still 
in need of further improvement and development.
Sperm banking is now considered the first line FP option 
for male patients; oocytes vitrification is currently considered 
the first line option for postpuberal female patients in which it 
is possible to delay chemotherapy and hormonal stimulation 
is authorized. Embryo banking gets in ethical conflict when 
it comes to preserving fertility, as healthcare's aim is to solely 
preserve the woman's fertility, which is the reason why it is 
not considered the first‑line treatment anymore. Furthermore, 
growing evidence of safety and efficiency success in oocyte 
vitrification, upholds this technique to be the preferred one. 
When facing a therapeutic emergency, or contraindication 
for hormonal stimulation exists, OTC or puncture of imma‑
ture oocytes are available. Immature oocytes will then be 
cryopreserved, directly or after being matured in vitro, to be 
vitrified as mature oocytes or as embryos after a fertilization 
technique (Fig. 1).
Among all the patients to whom these techniques address, 
pediatric and adolescent patients are the ones with the most 
restricted FP options (Fig. 2), higher survival rates, and thus 
those with the longest life expectancy. Therefore, special effort 
should be made to improve quality of life in this unique popu‑
lation and fulfill their reproductive wish.
As oncofertility is a recent concept and it is rapidly gaining 
importance, novel procedures involving emerging techno‑
logical advances are being developed. The in vitro activation 
of ovarian follicles has proven itself to be a very promising 
technique for future approaches, as it could be addressed 
to patients with restricted FP options: Prepubertal children, 
hormone‑sensitive tumors and those at urge to start treatment. 
OTC and subsequent transplantation, although still consid‑
ered experimental, is currently the only hope for prepubertal 
children (Fig. 2). This technique has shown encouraging 
results in adult patients, but literature regarding pregnancy in 
DEL‑POZO‑LÉRIDA et al:  FERTILITY PRESERVATION IN ONCOLOGICAL TREATMENT6
prepubertal children is very scarce. Only one live birth after 
autograft of cryopreserved tissue before menarche has been 
published (20).
Development of specific target chemotherapeutical 
treatment such as NB and the creation of artificial ovaries 
from stem cells, would respectively avoid and completely 
restore the ovarian function. Therefore, further development 
in these emerging techniques may lead to ground breaking 
advances of this field in the not so far future. Certainly, new 
FP techniques will continue to develop in the following 
years. However, despite the growing advances in the subject, 
optimal counselling from healthcare professionals is lacking.
In conclusion, FP in both female and male oncological patients 
is nowadays possible and should be integrated as part of the 
oncological health care. Different techniques exist and the most 
appropriate should be chosen depending on the characteristics of 
the patients: male, female, prepubertal or postpubertal. Many of 
the techniques are still in under experimental trials, whereas some 
others are standardized and established. Oocyte vitrification for 
female patients and sperm banking for male patients are now 
considered the first line FP option.
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